Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study on intravenous opioid agonist therapy with hydromorphone in Vienna
2022-002462-32Phase 2Active
- Sponsor
- Suchthilfe Wien
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydromorphone in opioid use disorder (OUD) and substance use disorder (SUD), sponsored by Suchthilfe Wien. Primary endpoint: Primary study endpoints. Started Oct 2022; status: active.
02
Drugs
hydromorphone
03
Conditions
opioid use disorder (OUD)substance use disorder (SUD)
Beyond the preview
Go deeper on 2022-002462-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002462-32.